v2.2
Contact
News
Diagnosing DIRD
Browse
Available on AppStore
The Drug-Induced Respiratory Disease Website
Philippe Camus, M.D.
Dijon, France
Browse by »
Drugs
Patterns
Biologics
5
X.b
Antiphospholipid antibodies w/wo the APL syndrome
1
Last update :
19/02/2022
Search
Search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist
See also under
Adalimumab
Aflibercept
Alemtuzumab
All-transretinoic acid (ATRA)
Anakinra
Antiplatelet agents: Glycoprotein IIb/IIIa inhibitors
Antithymocyte globulin (ATG-ALG) - Antithymocyte immunoglobulin (ATI)
Balsalazide
Basiliximab
Bevacizumab
Bortezomib
Certolizumab
Cetuximab
Crizotinib
DMARDs (disease-modifying antirheumatic drugs)
Dasatinib
Eptifibatide
Erlotinib
Etanercept
Everolimus
Fanolesomab-99mTc
G/GM-CSF
Gefitinib
Gemtuzumab
Golimumab
Imatinib
Infliximab
Interferon alpha/beta
Interferon gamma
Interleukin 2 (IL2)
Ipilimumab
Isotretinoin
Lambrolizumab
MTOR inhibitors
Matuzumab
Muromonab-CD3 (OKT3, orthoclone)
Natalizumab
Nilotinib
Nivolumab
Omalizumab
Palivizumab
Panitumumab
Pomalidomide
Ridaforolimus
Rituximab
Ruxolitinib
Sirolimus
Sorafenib
Sunitinib
TNF-alpha antagonists / inhibitors
Temsirolimus
Thalidomide
Tocilizumab
Tofacitinib
Tyrosine kinase inhibitors (EGFR) TKI
Ustekinumab
Vemurafenib
Zotarolimus
Publications
Drug-induced antiphospholipid syndrome: Analysis of the WHO international database.